Afzal Saira, Li Yadi, Lapin Brittany, Hua Le H, Kennedy Lucy Boyce, Ma Wen Wee, McGinley Marisa, Cohen Jeffrey A, Kunchok Amy
Department of Neurology, Cleveland Clinic Florida, Weston, Florida, USA.
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Ann Clin Transl Neurol. 2025 Mar;12(3):643-647. doi: 10.1002/acn3.52287. Epub 2024 Dec 31.
This study evaluated disease activity in people with Multiple Sclerosis (PwMS) who received immune checkpoint inhibitors (ICIs) compared to PwMS not treated with ICIs. There were 108 PwMS included (27 PwMS+ICIs and 81 PwMS controls), matched on age, sex, disease duration, DMTs, and MS disease course. Of 27 PwMS+ICIs, one (4%) had a relapse and four (15%) developed new MRI lesions without clinical symptoms. Time to relapse and MRI activity were compared using Kaplan-Meier curves and Cox regression models. There was no significant difference for either time to relapse (p = 0.34) or MRI activity (p = 0.15) in PwMS+ICIs compared to controls.
本研究评估了接受免疫检查点抑制剂（ICI）治疗的多发性硬化症患者（PwMS）与未接受ICI治疗的PwMS相比的疾病活动情况。共纳入108例PwMS（27例接受ICI治疗的PwMS和81例PwMS对照），在年龄、性别、病程、疾病修饰治疗（DMT）和多发性硬化症病程方面进行了匹配。在27例接受ICI治疗的PwMS中，1例（4%）出现复发，4例（15%）出现新的MRI病灶但无临床症状。使用Kaplan-Meier曲线和Cox回归模型比较复发时间和MRI活动情况。与对照组相比，接受ICI治疗的PwMS在复发时间（p = 0.34）或MRI活动情况（p = 0.15）方面均无显著差异。
